摘要
目的研究阿托伐他汀对不稳定型心绞痛(UA)患者高敏C-反应蛋白(hs-CRP)、肿瘤坏死因子α(TNFα)和肌钙蛋白(cTnI)的影响。方法选择2004年1月至2005年1月来我院就诊的126例UA患者为研究对象,随机分为两组:对照组62例,常规药物治疗(抗凝、硝酸酯类、β受体阻断剂、血管紧张素转换酶抑制剂和钙拮抗剂等)16周;阿托伐他汀干预组64例,在常规治疗基础上加用阿托伐他汀,每日80mg,治疗16周。分别于药物治疗前、治疗后16周采集空腹静脉血,测定血清hs-CRP、TNFα、cTnI浓度及血脂。结果药物治疗后,阿托伐他汀干预组血清hs-CRP、TNFα和cTnI浓度明显低于同期对照组(P<0.05)。结论阿托伐他汀降低UA患者血清hs-CRP、TNFa和cTnI浓度,从而降低ACS患者急性期病死率,改善心肌缺血症状,降低心血管事件的发生率。
Objective To investigate the effect of atorvastatin on blood levels of c-reactive protein （CRP）, tumor necrosis factor alpha（TNFα） and cardiac tropoin （cTnI） in patients with UA. Methods One hundred and twenty-six patients who underwent UA from January 2004 to 2005 in our hospital were randomized into two groups：control group ;atorvastatin group （80 mg/d）.Serum levels of CRP,TNFa ,cTnI and lipids （TC ,LDL-C） were measured before and after sixteen weeks treatment （in the early morning ）. Results The serum levels of CRP,TNFα and cTnl in atorvastatin group were distinctly lower than those in control group after the sixteen weeks treatment （P〈0.01）. Conclusion The result suggested that atorvastatin could significantly decrease the serum levels of CRP,TNFα and cTnI in patients with UA.
出处
《中国心血管病研究》
CAS
2006年第4期270-271,共2页
Chinese Journal of Cardiovascular Research
